Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

etesevimab

Eli Lilly HQ

Lilly wins European approval for lung cancer drug Portrazza

First biologic licenced in EU as a first-line treatment for adults with NSCLC

- PMLiVE

Pharma forms Parkinson’s disease trials consortium

Hopes to make clinical trials “smarter” through sharing of past PD trial data

- PMLiVE

The EMA’s literature screening service and pharma

Complexities and new potential in pharmacovigilance

Eli Lilly HQ

UK court backs Actavis in dispute over Lilly’s Alimta

Actavis’ generic version ruled not to infringe Lilly’s intellectual property

dengue fever mosquito

EMA creates Zika virus task force

Will aid research and development of vaccines and medicines

Digital roundup

Genzyme, Merck, the forthcoming EU clinical trials portal and more

- PMLiVE

AstraZeneca wins European approval for Tagrisso

The first-in-class lung cancer treatment receives a conditional licence

EU flag

EMA unveils draft guidelines for Alzheimer’s disease research

Puts plans for evaluating potential new therapies out for consultation

- PMLiVE

Empliciti on track for European approval in multiple myeloma

CHMP backs BMS and AbbVie's therapy after an accelerated assessment

Eli Lilly HQ

Eli Lilly files oral rheumatoid arthritis drug baricitinib in US

Hopes for approval later this year after the drug outperformed Humira in trials

EU flag

Nine positive opinions for new drugs at CHMP meeting

Tagrisso, Zurampic and Portrazza among the latest recommendations

- PMLiVE

Bayer defends Xarelto as pivotal trial scrutinised

ROCKET AF trial results questioned after some INRATIO devices used in testing recalled

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links